By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BerGenBio AS 

Thormohlensgt 51, 5006

  Bergen    Norway
Phone: 47-535-01-564 Fax: n/a



Company News
BerGenBio AS Release: BGB324 Enhances Immune Checkpoint Inhibitor Efficacy In Preclinical Cancer Models 9/21/2015 9:10:59 AM
BerGenBio AS Awarded 2015 Nordic Stars Award 9/14/2015 11:43:57 AM
AMRA, BerGenBio AS And Nexstim Receive Nordic Stars 2015 Awards At NLSDays In Stockholm 9/14/2015 11:42:49 AM
BerGenBio AS Awarded 2015 Nordic Stars Award 9/11/2015 10:16:24 AM
BerGenBio AS Appoints Non-Executive Directors 9/1/2015 6:51:44 AM
BerGenBio AS Initiates NSCLC Clinical Trial With BGB324 In Combination With erlotinib 6/10/2015 6:39:15 AM
BerGenBio AS Release: BGB324 And BGB10C9 Show Promise In Models Of Pancreatic Cancer 6/1/2015 7:51:18 AM
BerGenBio AS Completes NOK90 Million Fundraising 12/15/2014 7:47:21 AM
BerGenBio AS Receives Orphan-Drug Designation From FDA For BGB324 In The Treatment Of Acute Myeloid Leukaemia 11/19/2014 11:31:38 AM
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial 11/4/2014 7:41:49 AM